Dose – response relationship of bevacizumab in hereditary hemorrhagic telangiectasia

mAbs

Volumn 7, Issue 3, 2015, Pages 630-637

  Azzopardi, Nicolas ^a   Dupuis Girod, Sophie ^b,c   Ternant, David ^a,d   Fargeton, Anne Emmanuelle ^b   Ginon, Isabelle ^e   Faure, Frédéric ^f   Decullier, Evelyne ^b,c   Roux, Adeline ^b,c   Carette, Marie France ^g   Gilbert Dussardier, Brigitte ^h   Hatron, Pierre Yves ⁱ   Lacombe, Pascal ^j   Leguy Seguin, Vanessa ^k   Rivière, Sophie ^l   Corre, Romain ^m   Bailly, Sabine ^n,o,p   Paintaud, Gilles ^a,d  

^a UNIVERSITÉ DE TOURS   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d UNIVERSITY HOSPITAL OF TOURS   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f EDOUARD HERRIOT HOSPITAL   (France)

^g SORBONNE UNIVERSITÉ   (France)

^h POITIERS UNIVERSITY HOSPITAL   (France)

ⁱ UNIV LILLE   (France)

^j HÔPITAL AMBROISE PARÉ   (France)

^k Hôpital de Dijon   (France)

^l MONTPELLIER UNIVERSITY HOSPITAL   (France)

^m PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

ⁿ INSERM   (France)

^o CEA GRENOBLE   (France)

^p UNIV GRENOBLE ALPES   (France)

more..

Author keywords

Angiogenesis factors; Angiogenic; Antiangiogenesis agents; Bevacizumab; Dose response relationship; Hereditary hemorrhagic telangiectasia; Pharmacokinetics

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DYSPNEA; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPISTAXIS; FEMALE; HEART INDEX; HEART OUTPUT; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PROSPECTIVE STUDY; RENDU OSLER WEBER DISEASE; BIOLOGICAL MODEL; BLOOD; MIDDLE AGED; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

ADULT; AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 84944344371     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1022693     Document Type: Article

References (18)

1. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91: 66-7; PMID: 10751092; http://dx. doi. org/10. 1002/(SICI)1096-8628(20000306) 91: 1%3c66:: AID-AJMG12%3e3. 0. CO; 2-P.
2. David L, Mallet C, Keramidas M, Lamandé N, Gasc JMM, Dupuis-Girod S, Plauchu H, Feige J-JJ, Bailly S. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res 2008; 102: 914-22; PMID: 18309101; http://dx. doi. org/10. 1161/CIRCRESAHA. 107. 165530.
3. Sadick H, Riedel F, Naim R, Goessler U, Hörmann K, Hafner M, Lux A, Hormann K. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 2005; 90: 818-28; PMID: 15951295.
4. Dupuis-Girod S, Ginon I, Saurin J-C, Marion D, Guillot E, Decullier E, Roux A, Carette M-F, Gilbert-Dussardier B, Hatron P-Y, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 2012; 307: 948-55; PMID: 22396517; http://dx. doi. org/10. 1001/jama. 2012. 250.
5. Lu J-F, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008; 62: 779-86; PMID: 18205003; http://dx. doi. org/10. 1007/s00280-007-0664-8.
6. Li J, Gupta M, Jin D, Xin Y, Visich J, Allison DE. Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. Cancer Chemother Pharmacol 2013; 71: 575-80; PMID: 23228985; http://dx. doi. org/10. 1007/s00280-012-2031-7.
7. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002; 20: 4713-21; PMID: 12488418; http://dx. doi. org/10. 1200/JCO. 2002. 02. 140.
8. Ternant D, Cézé N, Lecomte T, Degenne D, Duveau A-C, Watier H, Dorval E, Paintaud G. An enzymelinked immunosorbent assay to study bevacizumab pharmacokinetics. Ther Drug Monit 2010; 32: 647-52; PMID: 20720519; http://dx. doi. org/10. 1097/FTD. 0b013e3181ef582a.
9. R Core Team. Computational many-particle physics. Berlin, Heidelberg: Springer Berlin Heidelberg; 2008.
10. Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 2007; 9: E60-83; PMID: 17408237; http://dx. doi. org/10. 1208/aapsj0901007.
11. Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol 2006; 72: 1-10; PMID: 16469301; http://dx. doi. org/10. 1016/j. bcp. 2005. 12. 041.
12. Stefanini MO, Wu FTH, Mac Gabhann F, Popel AS. Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res 2010; 70: 9886-94; PMID: 21118974; http://dx. doi. org/10. 1158/0008-5472. CAN-10-1419.
13. Bellissant E, Sébille V, Paintaud G. Methodological issues in pharmacokinetic-pharmacodynamic modelling. Clin Pharmacokinet 1998; 35: 151-66; PMID: 9739481; http://dx. doi. org/10. 2165/00003088-199835020-00004.
14. Bonate PL. The effect of collinearity on parameter estimates in nonlinear mixed effect models. Pharm Res 1999; 16: 709-17; PMID: 10350015; http://dx. doi. org/10. 1023/A: 1018828709196.
15. Maitre PO, Bührer M, Thomson D, Stanski DR. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm 1991; 19: 377-84; PMID: 1920085; http://dx. doi. org/10. 1007/BF01061662.
16. Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008; 90: 154-66; PMID: 18215437; http://dx. doi. org/10. 1016/j. cmpb. 2007. 12. 002.
17. Holford N, Ma SC, Ploeger BA. Clinical trial simulation: a review. Clin Pharmacol Ther 2010; 88: 166-82; PMID: 20613720; http://dx. doi. org/10. 1038/clpt. 2010. 114.
18. Milligan PA, Brown MJ, Marchant B, Martin SW, van der Graaf PH, Benson N, Nucci G, Nichols DJ, Boyd RA, Mandema JW, et al. Model-based drug development: a rational approach to efficiently accelerate drug development. Clin Pharmacol Ther 2013; 93: 502-14; PMID: 23588322; http://dx. doi. org/10. 1038/clpt. 2013. 54.